iA Global Asset Management Inc. Grows Stock Position in Inari Medical, Inc. (NASDAQ:NARI)

iA Global Asset Management Inc. lifted its holdings in Inari Medical, Inc. (NASDAQ:NARI) by 4.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 109,130 shares of the company’s stock after purchasing an additional 4,720 shares during the period. iA Global Asset Management Inc. owned about 0.19% of Inari Medical worth $5,571,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Vestal Point Capital LP boosted its holdings in shares of Inari Medical by 342.9% during the 3rd quarter. Vestal Point Capital LP now owns 1,550,000 shares of the company’s stock worth $63,922,000 after purchasing an additional 1,200,000 shares during the last quarter. Jennison Associates LLC increased its position in shares of Inari Medical by 63.2% during the third quarter. Jennison Associates LLC now owns 1,576,641 shares of the company’s stock worth $65,021,000 after acquiring an additional 610,468 shares during the period. The Manufacturers Life Insurance Company increased its position in shares of Inari Medical by 101.3% during the third quarter. The Manufacturers Life Insurance Company now owns 795,099 shares of the company’s stock worth $32,790,000 after acquiring an additional 400,198 shares during the period. Bamco Inc. NY increased its holdings in Inari Medical by 29.5% in the third quarter. Bamco Inc. NY now owns 1,006,129 shares of the company’s stock valued at $41,493,000 after buying an additional 228,977 shares during the last quarter. Finally, Point72 DIFC Ltd purchased a new position in Inari Medical in the third quarter valued at $9,008,000. Hedge funds and other institutional investors own 90.98% of the company’s stock.

Inari Medical Price Performance

Shares of NARI opened at $79.97 on Friday. The company’s fifty day moving average is $79.80 and its 200-day moving average is $59.81. Inari Medical, Inc. has a 12 month low of $36.73 and a 12 month high of $79.99. The firm has a market cap of $4.68 billion, a price-to-earnings ratio of -59.24 and a beta of 1.02.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Wells Fargo & Company restated an “equal weight” rating and issued a $80.00 price objective (up previously from $65.00) on shares of Inari Medical in a research note on Tuesday, January 7th. Oppenheimer assumed coverage on shares of Inari Medical in a report on Tuesday, December 17th. They set an “outperform” rating and a $75.00 price target for the company. Piper Sandler increased their price target on shares of Inari Medical from $52.00 to $80.00 and gave the stock a “neutral” rating in a report on Tuesday, January 7th. Canaccord Genuity Group reiterated a “hold” rating and set a $80.00 price target (up from $74.00) on shares of Inari Medical in a research report on Tuesday, January 7th. Finally, Robert W. Baird restated a “neutral” rating and set a $80.00 price objective (down from $81.00) on shares of Inari Medical in a research report on Tuesday, January 7th. Twelve analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $68.00.

Insider Activity at Inari Medical

In other news, Director William Hoffman sold 200,000 shares of the firm’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $60.47, for a total transaction of $12,094,000.00. Following the completion of the transaction, the director now directly owns 238,987 shares of the company’s stock, valued at approximately $14,451,543.89. This trade represents a 45.56 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 10.60% of the stock is currently owned by company insiders.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.